Pharmacological inhibition of LAP in patient-derived monocytes or LAP genetic disruption in mice exacerbated inflammation and fibrosis after CCl4-induced liver injury whereas enhancing LAP reduced inflammation and liver fibrosis (201). The gene discussed is TGFB1; the disease is Hepatic fibrosis.